LevelBlue’s 2025 Spotlight Report warns manufacturers face rising AI-driven threats with limited readiness, making cyber resilience a business imperative ...
Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025Enrollment of the First Subject into ...
Immunotherapy has transformed the treatment of cancer, yet many patients do not have response or lasting benefit. Strategies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback